DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Riverstone Advisors LLC

Riverstone Advisors LLC lowered its position in DexCom, Inc. (NASDAQ:DXCM) by 6.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 47,238 shares of the medical device company’s stock after selling 3,032 shares during the quarter. DexCom comprises about 3.8% of Riverstone Advisors LLC’s holdings, making the stock its 9th biggest holding. Riverstone Advisors LLC’s holdings in DexCom were worth $5,862,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Norges Bank acquired a new stake in DexCom in the fourth quarter valued at approximately $421,378,000. Winslow Capital Management LLC acquired a new stake in DexCom during the third quarter worth approximately $173,120,000. Vaughan Nelson Investment Management L.P. raised its holdings in DexCom by 16,943.0% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 1,459,730 shares of the medical device company’s stock worth $136,193,000 after purchasing an additional 1,451,165 shares in the last quarter. 1832 Asset Management L.P. acquired a new stake in DexCom during the fourth quarter worth approximately $151,538,000. Finally, Clearbridge Investments LLC raised its holdings in DexCom by 304.3% during the first quarter. Clearbridge Investments LLC now owns 1,318,079 shares of the medical device company’s stock worth $674,329,000 after purchasing an additional 992,049 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the transaction, the chief executive officer now directly owns 333,526 shares in the company, valued at $44,479,027.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the transaction, the chief executive officer now directly owns 333,526 shares in the company, valued at $44,479,027.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jereme M. Sylvain sold 3,363 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the sale, the chief financial officer now owns 71,142 shares in the company, valued at $8,304,405.66. The disclosure for this sale can be found here. Insiders have sold 187,385 shares of company stock worth $25,256,617 over the last ninety days. 0.41% of the stock is owned by insiders.

DexCom Stock Up 1.7 %

NASDAQ:DXCM traded up $2.24 during trading hours on Tuesday, hitting $136.80. The stock had a trading volume of 1,387,570 shares, compared to its average volume of 2,968,482. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The business has a 50 day simple moving average of $128.82 and a two-hundred day simple moving average of $115.85. The company has a market cap of $52.74 billion, a PE ratio of 102.72, a price-to-earnings-growth ratio of 2.34 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the company earned $0.34 earnings per share. The business’s quarterly revenue was up 26.9% compared to the same quarter last year. Analysts predict that DexCom, Inc. will post 1.76 EPS for the current year.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of research analyst reports. Royal Bank of Canada initiated coverage on shares of DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective on the stock. StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Piper Sandler boosted their target price on shares of DexCom from $135.00 to $150.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 19th. Citigroup lifted their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, UBS Group boosted their target price on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $141.40.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.